Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGAINST-PLD: Leuprorelin to Halt Disease Progression in Polycystic Liver Disease
2023-506637-30-00Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in Polycystic liver disease (PLD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Liver growth rate between direct and delayed start groups. Started Nov 2024; status: completed.
02
Drugs
leuprolide
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on 2023-506637-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506637-30-00.